Biocryst Pharma Inc (BCRX)

$7.33 -0.10 (-1.35%)
Market Cap 1.51B
Revenue (ttm) 450.71M
Net Income (ttm) -88.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -19.72%
Debt to Equity Ratio -1.74
Volume 3,074,200
Avg Vol 3,374,358
Day's Range N/A - N/A
Shares Out 208.96M
Stochastic %K 3%
Beta 1.75
Analysts Strong Sell
Price Target $14.73

Latest News on BCRX

BioCryst to Present at Upcoming Investor Conference

Apr 2, 2025, 4:01 PM EDT - 1 day ago

BioCryst to Present at Upcoming Investor Conference

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 7:00 AM EST - 4 weeks ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 9:09 AM EST - 5 weeks ago

BioCryst: Orladeyo's Expansion Is Just Getting Started

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

Feb 26, 2025, 7:45 AM EST - 5 weeks ago

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Feb 25, 2025, 6:24 PM EST - 5 weeks ago

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 12:17 PM EST - 5 weeks ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Feb 24, 2025, 11:49 AM EST - 5 weeks ago

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 7:00 AM EST - 5 weeks ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

Feb 24, 2025, 6:00 AM EST - 5 weeks ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

BioCryst to Present at Upcoming Investor Conferences

Feb 19, 2025, 7:00 AM EST - 6 weeks ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 12, 2025, 7:00 AM EST - 7 weeks ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 8:30 AM EST - 7 weeks ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Feb 10, 2025, 7:00 AM EST - 7 weeks ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 10, 2025, 7:00 AM EST - 2 months ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 3 months ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Dec 9, 2024, 1:47 PM EST - 4 months ago

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

Nov 18, 2024, 2:00 AM EST - 4 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:00 AM EST - 5 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

BioCryst to Report Third Quarter 2024 Financial Results on November 4

Oct 21, 2024, 7:00 AM EDT - 5 months ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Oct 14, 2024, 7:00 AM EDT - 6 months ago

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Oct 2, 2024, 7:00 AM EDT - 6 months ago

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

Sep 30, 2024, 7:00 AM EDT - 6 months ago

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

Sep 17, 2024, 7:00 AM EDT - 7 months ago

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

Sep 6, 2024, 2:00 AM EDT - 7 months ago

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 11:44 AM EDT - 8 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 8 months ago

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Jul 22, 2024, 7:00 AM EDT - 9 months ago

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21, 2024, 7:30 AM EDT - 9 months ago

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

ORLADEYO® (berotralstat) Approved in Peru

Jul 9, 2024, 7:00 AM EDT - 9 months ago

ORLADEYO® (berotralstat) Approved in Peru

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

Jun 2, 2024, 4:00 AM EDT - 10 months ago

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

May 14, 2024, 7:00 AM EDT - 11 months ago

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

ORLADEYO® (berotralstat) Approved in Mexico

May 13, 2024, 7:00 AM EDT - 11 months ago

ORLADEYO® (berotralstat) Approved in Mexico

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

May 9, 2024, 7:00 AM EDT - 11 months ago

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:42 AM EDT - 11 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 7:00 AM EDT - 11 months ago

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

BioCryst to Report First Quarter 2024 Financial Results on May 6

Apr 22, 2024, 7:00 AM EDT - 1 year ago

BioCryst to Report First Quarter 2024 Financial Results on May 6

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

Apr 17, 2024, 4:30 AM EDT - 1 year ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:29 AM EST - 1 year ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

Feb 26, 2024, 7:00 AM EST - 1 year ago

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

Feb 23, 2024, 7:00 AM EST - 1 year ago

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

BioCryst Launches ORLADEYO® (berotralstat) in Italy

Feb 19, 2024, 7:54 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Italy

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

Feb 12, 2024, 7:00 AM EST - 1 year ago

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 5, 2024, 7:00 AM EST - 1 year ago

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

Jan 5, 2024, 4:01 PM EST - 1 year ago

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

Dec 19, 2023, 7:00 AM EST - 1 year ago

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely

Dec 14, 2023, 6:34 PM EST - 1 year ago

BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

Nov 29, 2023, 7:00 AM EST - 1 year ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

BioCryst Launches ORLADEYO® (berotralstat) in Spain

Nov 21, 2023, 7:00 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Spain

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

Nov 10, 2023, 7:00 AM EST - 1 year ago

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)